No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ARWR240816P25000
- 0.55
- -0.15-21.43%
15min DelayClose Jul 22 15:55 ET
0.80High0.55Low
0.60Open0.70Pre Close492 Volume89 Open Interest25.00Strike Price28.31KTurnover66.88%IV14.96%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.55Extrinsic Value100Contract SizeAmericanOptions Type-0.1835Delta0.0526Gamma52.27Leverage Ratio-0.0260Theta-0.0037Rho-9.59Eff Leverage0.0201Vega
Intraday
- 5D
- Daily
News
Analysts' Opinions Are Mixed on These Healthcare Stocks: CSL (OtherCMXHF) and Arrowhead Pharmaceuticals (ARWR)
Arrowhead Pharmaceuticals Price Target Maintained With a $60.00/Share by Chardan Capital
Arrowhead Pharmaceuticals Price Target Maintained With a $60.00/Share by Chardan
Arrowhead Pharmaceuticals Is Maintained at Buy by Chardan Capital
Arrowhead Pharmaceuticals Is Maintained at Buy by Chardan
BofA Securities Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $54
BofA Securities analyst Jason Gerberry maintains $Arrowhead Pharmaceuticals(ARWR.US)$ with a buy rating, and maintains the target price at $54.According to TipRanks data, the analyst has a success
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $62
Piper Sandler analyst Edward Tenthoff maintains $Arrowhead Pharmaceuticals(ARWR.US)$ with a buy rating, and maintains the target price at $62.According to TipRanks data, the analyst has a success
TD Cowen Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)
Comments
Plozasiran reduced triglycerides and APOC3 up to a mean maximum of 86% and 90% respectively in patients with severe hypertriglyceridemia
$Arrowhead Pharmaceuticals(ARWR.US$
$Arrowhead Pharmaceuticals(ARWR.US$
1
$Arrowhead Pharmaceuticals(ARWR.US$
Insiderd selling shares and financials dont look good. Im guessing they dont have anything in the pipeline?
Insiderd selling shares and financials dont look good. Im guessing they dont have anything in the pipeline?
The company's poor performance and the CEO's high pay, despite falling earnings and shareholder value, may upset shareholders. The upcoming AGM on March 14th is a chance for shareholders to hold the board and management accountable.
$Arrowhead Pharmaceuticals(ARWR.US$ why drop today?
$Arrowhead Pharmaceuticals(ARWR.US$ such a odd spot here
Read more